This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
The major US stock index benchmarks were off their lows late in the trading session, with the NASDAQ 100 closest to breaking even, down just 0.1% at 3073, helped by a 4% rise in Facebook, which is still benefitting from its strong quarterly report that it released last week.
The Dow Jones was down 0.23% while the S&P 500 fell 0.27%. The volatility index rose more than 1%, suggesting edginess in the market ahead of central bank meetings this week from the FOMC , the ECB and the Bank of England.
With no news from the Fed until late on Wednesday, the financial markets are likely to remain nervy and possibly quite choppy until then.
Of course, the central bank meetings are far from the only things going on this week. Although reports have been fairly light for the last couple of trading sessions, we are in the middle of the US reporting season. This week will not be as packed with as many big names reporting as last, but tomorrow we will hear from Dow components Merck and Pfizer, among others.